The news: Shares in Telix Pharmaceutical climbed in morning trade after the company reported positive results from a global phase 3 trial of its advanced prostate cancer treatment, TLX591. Shares ...

Nurses and advanced practice registered nurses (APRNs) play a central role in preventive care, screening, chronic disease management, and patient education. Expanding this workforce is particularly ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ...

Researchers found men who ejaculated more often had fewer prostate cancer diagnoses, pointing to a possible biological ...

Cancers of the reproductive and urinary organs, known as genitourinary cancers, affect millions of people worldwide each year ...

The FDA will end a roughly nine-month hiatus of drug-related advisory committee meetings, with plans to convene its first session of 2026 to scrutinize a pair of oncology applications from AstraZen | ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

Oxybutynin significantly reduced hot flash frequency and severity compared with placebo among men with prostate cancer ...

The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.